Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study.

Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study. Eligible cases will be assigned into the experimental group and the control group. For experiment group, sorafenib tablet will be given for two weeks, and then perform radiofrequency ablation. For the control group, RFA will be performed immediately.

Inclusion Criteria:

• Aged from 18 to 75 years old
• Without gender restriction
• With a favorable liver function of Child-Pugh A to B
• No contraindications to RFA and anesthesia
• Diagnosed with Recurrent HCC
• Signed informed consent.

Exclusion Criteria:

• Cancer thrombosis in major vessels/ extrahepatic metastasis
• Uncontrollable ascites or variceal bleeding
• Impairment in liver function
• Severe disorders in vital organ
• Accompanied with other tumors or infectious disease except hepatitis.